Genomic landscape of acquired resistance to third‐generation EGFR tyrosine kinase inhibitors in EGFR T790M‐mutant non–small cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Genomic landscape of acquired resistance to third‐generation EGFR tyrosine kinase inhibitors in EGFR T790M‐mutant non–small cell lung cancer

Published:2020-03-10 Issue:11 Volume:126 Page:2704-2712
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Lee Jiyun¹,Kim Hong Sook¹²,Lee Boram³⁴^ORCID,Kim Hee Kyung¹,Sun Jong‐Mu¹,Ahn Jin Seok¹,Ahn Myung‐Ju¹^ORCID,Park Keunchil¹^ORCID,Lee Se‐Hoon¹³^ORCID

Affiliation:

1. Division of Hematology‐Oncology Department of Medicine Samsung Medical Center Sungkyunkwan University School of Medicine Seoul Korea

2. Department of Biological Sciences Sungkyunkwan University Suwon Korea

3. Department of Health Sciences and Technology Samsung Advanced Institute of Health Science and TechnologySungkyunkwan University Seoul Korea

4. Samsung Genome Institute Samsung Medical Center Sungkyunkwan University Seoul Korea

Funder

Ministry of Trade, Industry and Energy

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32809

Reference39 articles.

1. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

2. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

3. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

4. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

5. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts;Cancer Research Communications;2024-09-01

2. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24

3. Therapeutic advances of targeting receptor tyrosine kinases in cancer;Signal Transduction and Targeted Therapy;2024-08-14

4. The impact of EGFR T790M mutation status following the development of Osimertinib resistance on the efficacy of Osimertinib in non‐small cell lung cancer: A meta‐analysis;The Clinical Respiratory Journal;2024-04

5. Brigatinib, a newly discovered AXL inhibitor, suppresses AXL-mediated acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer;Acta Pharmacologica Sinica;2024-03-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3